Oncology

Latest News

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com

Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.

Insurance gaps | Image Credit: iQoncept-stock.adobe.com

Insurance Gaps Threaten Cancer Treatment Success

By Maggie L. Shaw

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 13th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 13th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

October 6th 2018

Merkel Cell Carcinoma in the United States: Prognostics and Treatment Options

Jaime Rosenberg

Narrowing in on neuroendocrine skin cancer, a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, took an in-depth look at prognostics and treatment options for Merkel cell carcinoma in the United States.

October 6th 2018

Debating Best First-Line Treatment in Well-Differentiated G3 NENs

Jaime Rosenberg

During a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, panelists debated whether newer targeted agents should be considered for first-line treatment in well-differentiated G3 neuroendocrine neoplasms (NENs), and if the standard of care—cytotoxic therapy—should still play a role in first-line treatment.

October 5th 2018

Cancer Types Can Impact How Well Providers May Perform Under OCM

Laura Joszt, MA

The type of cancer a provider treats can determine how well he or she performs under the Oncology Care Model (OCM), according to research from Avalere Health that was presented at the American Society of Clinical Oncology Quality Care Symposium.

October 5th 2018

Examining the Benefits of Integrative Oncology, Nutrition in NETs

Jaime Rosenberg

During a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, panelists discussed the benefits of integrative oncology and nutrition for patients with neuroendocrine tumors.

October 5th 2018

Dr Heloisa Soares Discusses the Roles of Somatostatin Analogs in GEP-NETs

Somatostatin analogs have 2 roles in gastroenteropancreatic neuroendocrine tumors (GEP-NETS): treating symptoms related to the tumors and controlling tumor growth, explained Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque.

October 5th 2018

Analysis Demonstrates Effectiveness, Patient Satisfaction With Lanreotide in GEP-NETs

Jaime Rosenberg

An interim analysis of somatostatin analog lanreotide depot presented at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, found that the treatment was effective in disease control and most patients were satisfied with the treatment.

October 5th 2018

Measuring Quality of Life Among Patients With Neuroendocrine Tumors

Jaime Rosenberg

Two studies presented at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington assessed different tools for determining quality of life among patients with neuroendocrine tumors (NETs).

October 5th 2018

Preventing Antimicrobial Complications, Ensuring Stewardship in Cancer Care

Allison Inserro

This week, infectious disease specialists from different organizations are meeting in San Francisco for ID Week, an annual conference focused on many different infectious disease topics and their intersection with cancer, HIV, respiratory diseases, and more. Two abstracts presented results about what is needed to prevent complications in cancer care, one about patients with acute myeloid leukemia (AML) with prolonged neutropenia, and one examining the frequency of antimicrobial complications following initiation of palliative chemotherapy.

October 4th 2018

Making the Leap to Prospective Risk in Value-Based Oncology Care

Mary Caffrey

The Institute for Value-Based Medicine travels to New York City to learn how technology and trust are key to making the leap to two-sided risk.

October 4th 2018

Recent Study on Site of Care Has Severe Limitations

Lucio N. Gordan, MD Debra Patt, MD

The outpatient community oncology setting is consistently less costly for cancer treatment as opposed to the outpatient hospital setting.

October 4th 2018

The Authors Respond and Stand Behind Their Findings

Yamini Kalidindi, MHA Jeah Jung, PhD Roger Feldman, PhD

Our study provides the first evidence on site-specific Medicare spending on chemotherapy adjusting for patient comorbid illnesses, cancer type, and other cancer-related risks.

October 3rd 2018

FDA Approves Once-Weekly Dose of Kyprolis for R/R Multiple Myeloma

Laura Joszt, MA

A once-weekly dose of carfilzomib (Kyprolis) in combination with dexamethasone has been approved to treat patients with relapsed or refractory (R/R) multiple myeloma. The approved regimen improved progression-free survival and had a better overall response rate than a twice-weekly regimen.

October 3rd 2018

Employers Take a Vested Interest in Healthcare

Employers may not look forward to purchasing healthcare, but they are in the position to transform the market. More employers are getting more involved in healthcare by championing alternative payment models and other services to their employees.

October 2nd 2018

People Living With HIV Have Higher Risk of First and Second Primary Cancer Incidence

Jaime Rosenberg

A new study has found that people living with HIV are at an increased risk of both first and second primary cancer incidence.

October 2nd 2018

FDA Approves NGS-Based Test That Detects Very Low Levels of Cancer Cells in ALL or MM

Laura Joszt, MA

A test that uses next-generation sequencing (NGS) has been approved to detect and monitor minimal residual disease in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL).

September 30th 2018

Top 5 AJMC® Articles of September 2018

Here are the top 5 articles for the month of September.

September 30th 2018

Working Toward CAR T-Cell Treatments With Fewer Side Effects

Mary Caffrey

Loyola University Chicago and Loyola Medicine announced plans this week to develop their own chimeric antigen receptor T-cells that would have less toxic side effects.

September 29th 2018

Lack of Discussion Around Cancer Treatment Costs Leads to Financial Toxicity

Samantha DiGrande

Earlier this week, 3 studies were released that investigated the financial difficulties seen in patients living with cancer. Such difficulties are referred to as “financial toxicity,” which was studied in patients with metastatic breast cancer and older patients, as well as the conversations about cost of care that women with breast cancer have with their physicians.

September 28th 2018

Imfinzi Plus Chemotherapy Reduced Risk of Death by One-Third in Stage III NSCLC

Samantha DiGrande

Earlier this week, drug manufacturer Astrazeneca announced the results from a phase 3 trial studying durvalumab (Imfinzi) among patients with stage III unresectable non–small cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy.

September 26th 2018

The Risk of Creating Healthcare Monopolies

September 26th 2018

Burnout and Resilience Among Oncologists

September 26th 2018

Healthcare Payment Models

September 26th 2018

Oncology Care Within Integrated Delivery Networks

September 26th 2018

The Unique Case of the VA Model

September 26th 2018

Best-in-Class Healthcare Delivery Models

September 26th 2018

Integrated Delivery Networks

September 26th 2018

The Role of Medium-Sized Employers

September 26th 2018

Large Employers and Healthcare Consolidation

September 26th 2018

The Impact of Consolidation on Healthcare Stakeholders

September 26th 2018

Potential Benefits of Healthcare Consolidation

...

38 39 40 41 42 43 44 45 46

...

186 >